PCN14 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MÉXICO

Authors:
  • AJA Juarez-Garcia
    A Juarez-Garcia
  • RUR Uc-Coyoc
    R Uc-Coyoc
  • GHG Hernandez-Rivera
    G Hernandez-Rivera
  • SRS Rangel
    S Rangel
  • MTMj Taylor
    Mj Taylor
  • GLG Litalien
    G Litalien
  • BDB Donato
    B Donato

Abstract
No abstract available